BUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data

Reuters01-30

BUZZ-<a href="https://laohu8.com/S/JYB">Jyong Biotech</a> rises on prostate cancer drug mid‑stage trial data

** Shares of drugmaker Jyong Biotech MENS.O rise 2.68% to $2.63 premarket

** Co says its experimental drug, MCS‑8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland

** Co says men on MCS‑8 had a 27% lower chance of developing prostate cancer vs placebo in a mid‑stage trial

** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co

** Co says no serious side effects reported; long‑term use did not affect liver, kidney or blood pressure

** MENS is considering expanding use of MCS‑8 for high cholesterol and heart disease, co says

** Shares up ~43% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607344046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607344046","market":"us","top_or_hot":-1,"title":"BUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/JYB\">Jyong Biotech</a> rises on prostate cancer drug mid‑stage trial data</title></head><body><p>** Shares of drugmaker <span>Jyong Biotech </span><span>MENS.O</span> rise 2.68% to $2.63 premarket</p><p>** Co says its experimental drug, MCS‑8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland</p><p>** Co says men on MCS‑8 had a 27% lower chance of developing prostate cancer vs placebo in a mid‑stage trial</p><p>** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co</p><p>** Co says no serious side effects reported; long‑term use did not affect liver, kidney or blood pressure</p><p>** MENS is considering expanding use of MCS‑8 for high cholesterol and heart disease, co says</p><p>** Shares up ~43% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/JYB\">Jyong Biotech</a> rises on prostate cancer drug mid‑stage trial data</title></head><body><p>** Shares of drugmaker <span>Jyong Biotech </span><span>MENS.O</span> rise 2.68% to $2.63 premarket</p><p>** Co says its experimental drug, MCS‑8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland</p><p>** Co says men on MCS‑8 had a 27% lower chance of developing prostate cancer vs placebo in a mid‑stage trial</p><p>** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co</p><p>** Co says no serious side effects reported; long‑term use did not affect liver, kidney or blood pressure</p><p>** MENS is considering expanding use of MCS‑8 for high cholesterol and heart disease, co says</p><p>** Shares up ~43% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MENS","symbol_name":"健永生技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL4N3YV1G0:1","article_id":"2607344046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607344046","pubTimestamp":1769780637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Jyong Biotech rises on prostate cancer drug midstage trial data** Shares of drugmaker Jyong Biotech MENS.O rise 2.68% to $2.63 premarket** Co says its experimental drug, MCS8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland** Co says men on MCS8 had a 27% lower chance of developing prostate cancer vs placebo in a midstage trial** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co** Co says no serious side effects reported; longterm use did not affect liver, kidney or blood pressure** MENS is considering expanding use of MCS8 for high cholesterol and heart disease, co says** Shares up ~43% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MENS":"健永生技","BK4139":"生物科技"},"translate_title":"BUZZ-Jyong Biotech因前列腺癌药物中期试验数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MENS":0.9},"content_text":"BUZZ-Jyong Biotech rises on prostate cancer drug mid‑stage trial data** Shares of drugmaker Jyong Biotech MENS.O rise 2.68% to $2.63 premarket** Co says its experimental drug, MCS‑8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland** Co says men on MCS‑8 had a 27% lower chance of developing prostate cancer vs placebo in a mid‑stage trial** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co** Co says no serious side effects reported; long‑term use did not affect liver, kidney or blood pressure** MENS is considering expanding use of MCS‑8 for high cholesterol and heart disease, co says** Shares up ~43% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607344046","isCrawlerRequest":true}